FDA Gives Fast Track Boost to Climb Bio’s Budoprutug for Primary Membranous Nephropathy
Climb Bio stock jumps after FDA fast-track for budoprutug, a new drug for rare kidney disease pMN.
/ 352 items
#XY Event-Driven Stocks↓
AC Immune & Lilly Team Up Again to Stop Alzheimer’s with Brain-Targeting Drugs
AC Immune updates Eli Lilly deal to develop pill-based Tau drugs for Alzheimer’s, aiming to stop disease early with promising preclinical results.
Organogenesis’ PuraPly AM Shows Strong Success in Diabetic Foot Ulcer Trial
Organogenesis Holdings says PuraPly AM helps diabetic foot ulcers heal faster than standard care alone in a clinical trial.
Insurer Stocks Soar After CMS Finalizes 2027 Medicare Payments
CMS boosts 2027 Medicare payments 2.5%, giving insurers $13B+, keeping plans stable and seniors’ benefits solid. Stocks jump.
ImmunityBio Quickly Fixes FDA Ad Concerns: Podcast Pulled, TV Spot Never Aired
ImmunityBio addressed FDA ad concerns, removed a podcast, and clarified ANKTIVA info while tightening rules on future promotions.
Vericel Secures Up to $197M BARDA Contract for NexoBrid – 10-Year Deal to Bolster U.S. Burn and Blast Injury Preparedness
Vericel won a 10-year, $197M BARDA deal to supply NexoBrid, a burn treatment, and expand its use and production in the U.S.